The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

82326382242082207926ffebf4-e819-4895-871b-9da9b95c581280e5f7dc-93a3-4b2c-8e4f-a382b1980df2fa0ccf27-165d-4d27-804c-06f4c7c8d873ARGS_News_2015_4_23_General_Releases.pdfARGS_News_2015_4_21_General_Releases.pdfARGS_News_2015_4_20_General_Releases.pdf1742120150168731232015-4-23T10:15:0-4:02015-4-21T8:30:0-4:02015-4-20T8:30:0-4:0908278907629907340General ReleasesGeneral ReleasesGeneral ReleasesDeveloper of Fully Personalized Immunotherapies Recently Broke Ground on 100,000 Square Foot Manufacturing Facility With Plans to Create Nearly 250 New Jobs in DurhamEncouraging Survival With the Combination of AGS-003 Plus Sunitinib in Unfavorable Risk mRCC Published in Journal for ImmunoTherapy of CancerFully Personalized Immunotherapy Based on the Arcelis(R) Technology Platform is Being Evaluated for the Treatment of Metastatic Renal Cell Carcinoma.Argos Therapeutics Recognized for Economic Development at the 17th Annual Triangle CREW Champion AwardsArgos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)Argos Therapeutics to Present Update on Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting949494201520152015No Error0

Argos Therapeutics Recognized for Economic Development at the 17th Annual Triangle CREW Champion Awards
Read more

Argos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)
Read more

Argos Therapeutics to Present Update on Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC